Sutro Biopharma, Inc. (STRO)
Largest Insider Buys in Sector
STRO Stock Price History Chart
STRO Stock Performance
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate …
Insider Activity of Sutro Biopharma, Inc.
Over the last 12 months, insiders at Sutro Biopharma, Inc. have bought $0 and sold $60,925 worth of Sutro Biopharma, Inc. stock.
On average, over the past 5 years, insiders at Sutro Biopharma, Inc. have bought $365,002 and sold $7.34M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $155,016 was made by NEWELL WILLIAM J (CEO) on 2022‑03‑14.
List of Insider Buy and Sell Transactions, Sutro Biopharma, Inc.
| 2024-01-29 | Sale | CHIEF PORT. STRAT & ALNCE OFCR | 12,185 0.0202% | $5.00 | $60,925 | -17.32% | ||
| 2023-08-28 | Sale | Chief Business Officer | 15,428 0.0253% | $4.71 | $72,595 | -15.93% | ||
| 2023-08-25 | Sale | Chief Business Officer | 11,613 0.0191% | $4.59 | $53,282 | -13.48% | ||
| 2022-03-14 | CEO | 20,000 0.0428% | $7.75 | $155,016 | -20.05% | |||
| 2021-09-28 | Sale | Chief Port. Strat & Alnce Ofcr | 7,812 0.0168% | $18.62 | $145,449 | -56.52% | ||
| 2021-01-26 | Sale | Chief Scientific Officer | 4,786 0.0109% | $25.71 | $123,056 | -22.66% | ||
| 2020-12-28 | Sale | Chief Scientific Officer | 4,786 0.0079% | $13.36 | $63,964 | -11.14% | ||
| 2020-11-27 | Sale | Chief Scientific Officer | 4,786 0.0081% | $10.69 | $51,147 | +17.02% | ||
| 2020-11-05 | Sale | Chief Scientific Officer | 33,502 0.061% | $9.68 | $324,299 | +38.31% | ||
| 2020-09-28 | Sale | Chief Scientific Officer | 1,950 0.0053% | $10.26 | $20,013 | +91.08% | ||
| 2020-09-18 | Sale | director | 800,000 2.1944% | $12.00 | $9.6M | +65.94% | ||
| 2020-09-11 | Sale | director | 1M 2.6591% | $10.00 | $10M | +89.12% | ||
| 2020-08-26 | Sale | Chief Scientific Officer | 975 0.0026% | $9.04 | $8,818 | +101.61% | ||
| 2020-08-19 | Sale | director | 1M 2.5584% | $8.72 | $8.72M | +102.44% | ||
| 2020-07-27 | Sale | Chief Science Officer | 975 0.0026% | $8.06 | $7,858 | +124.43% | ||
| 2020-06-26 | Sale | Chief Science Officer | 1,950 0.0072% | $8.02 | $15,635 | +156.49% | ||
| 2020-05-26 | Sale | Chief Science Officer | 1,950 0.0067% | $10.00 | $19,507 | +75.75% | ||
| 2020-05-14 | CEO | 64,516 0.2052% | $7.75 | $499,999 | +101.84% | |||
| 2020-05-14 | Chief Medical Officer | 6,451 0.0205% | $7.75 | $49,995 | +101.84% | |||
| 2020-05-14 | Chief People & Comm. Officer | 3,225 0.0103% | $7.75 | $24,994 | +101.84% |
Insider Historical Profitability
| Merck & Co., Inc. | 10 percent owner | 2723509 3.3029% | $2.66 | 1 | 0 | <0.0001% |
| NEWELL WILLIAM J | CEO | 116525 0.1413% | $2.66 | 2 | 0 | +40.89% |
| MOLINA ARTURO MD | Chief Medical Officer | 12083 0.0147% | $2.66 | 1 | 0 | +101.84% |
| FITZPATRICK LINDA A | Chief People & Comm. Officer | 9007 0.0109% | $2.66 | 1 | 0 | +101.84% |
Institutional Investor Ownership
| Suvretta Capital Management, LLC | $32.65M | 7.06 | 5.78M | 0% | +$0 | 1.38 | |
| BlackRock | $32.22M | 6.97 | 5.7M | -2.1% | -$689,396.05 | <0.01 | |
| Millennium Management LLC | $26.76M | 5.79 | 4.74M | +208.36% | +$18.08M | 0.02 | |
| Bioimpact Capital Llc | $23.15M | 5.01 | 4.1M | New | +$23.15M | 3.75 | |
| The Vanguard Group | $17.08M | 3.7 | 3.02M | +4.59% | +$750,263.48 | <0.0001 |